LED Medical Inc. Announces VELscope(R) Vx Results from REALITY Review

Print E-mail
By Marketwired - Medical and name brand cialis Healthcare   
Wednesday, 05 March 2014 13:10

BURNABY, BRITISH COLUMBIA--(Marketwired - March 5, 2014) - LED Medical Diagnostics Inc. ("LED Medical" or the "Company") (TSX VENTURE:LMD) (OTCQX:LEDIF) (FRANKFURT:LME) is pleased to announce that the VELscope® Vx Enhanced Oral Assessment System has received a REALITY'S CHOICES rating of 4.5 stars (out of a possible 5).

REALITY's evaluators were tasked with implementing the VELscope® Vx system into their practices and is there a generic cialis evaluating its features, including clinical utility, ease-of-operation, camera system use, and marketing materials.

The VELscope® Vx device was very well received by the evaluators and canadian healthcare the following strengths were highlighted:

  • Non-invasive;
  • Requires no rinses;
  • Solid research base ;
  • Well received by appreciative patients ;
  • Short examination time;
  • Convenient cordless design;
  • Easy to attach camera system enables clinicians to easily record images and viva viagra song monitor mucosal lesions.

Clinical Utility

"We are very pleased to receive a standout rating on the REALITY evaluation," states Dr. David Gane, CEO of LED Medical. "In addition to acknowledging the VELscope® Vx device as an improvement over its predecessor on many features, the REALITY evaluators also were able to detect mucosal lesions invisible to the naked eye and viagra india provide their patients with suitable follow-up."

According to REALITY: "Slightly more than half (57%) of evaluators found lesions that were not visible without using it, while the remaining 43% did not find any lesions during the evaluation period. Of those evaluators who found lesions, half decided to put them on watch and cialis canadian check them again in several months, 25% reported that no lesions were found to be malignant, and 25% found at least one malignant lesion. One evaluator found three areas of concern and viagra pills for sale referred to an oral surgeon. One area that was biopsied was malignant and generic soft viagra required extensive surgery."

"We were pleased to learn that VELscope® Vx technology helped the evaluators in the discovery of potentially pre-cancerous and cialis or vardenafil 20mg tablet cancerous tissues," states Dr. Gane. "The VELscope® Vx device is an imaging modality which is extremely sensitive to tissue changes, and its use in everyday practice can provide timely information to dentists and order cheap generic viagra hygienists to enable earlier detection of abnormal tissues and viagra in canada pfizer provide better outcomes for patients. "

About REALITY

REALITY (http://www.realityesthetics.com)is a full service information resource and viagra prescriptions product testing company, with its publications collectively considered the "bible of cosmetic dentistry." The Editorial Team has also grown to 37 of the most respected and who has the cheapest cialis highly renowned dental professionals in the world. With 9 international members on the Editorial Team, REALITY has become the final word in esthetics around the world. REALITY offers a full array of online services, such as REALITY ONLINE LECTURES and REALITY RESPONDS Q&A service. The REALITY ESTHETICS database contains 900 evaluations and previews covering general and esthetic products.

About VELscope®Vx Enhanced Oral Assessment

The distinctive blue-spectrum light of the VELscope® Vx Enhanced Oral Assessment System causes the soft tissues of the mouth to naturally fluoresce. Healthy tissues fluoresce in distinct patterns that are visibly disrupted by trauma or disease, such as neoplastic lesions, chemical irritation, side-effects from medication, thermal damage, fungal, viral or bacterial infections. Use of the VELscope® Vx adjunctive device allows a wide variety of oral abnormalities to be discovered, often before they become apparent to the unassisted eye. It is also the only tissue fluorescence device with photo/video documentation capabilities through the viewing mechanism, a key function for referrals and patient records.

Today VELscope® systems are used to conduct more examinations for oral cancer and other oral diseases than any other adjunctive device. To date, more than 12,000 VELscope® systems are in use globally and dental practitioners have performed more than 25 million exams.

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX-V) under the symbol "LMD", the OTCQX under the symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME". For more information, visit www.ledmd.com.

Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures the VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. For more information, call 604.434.4614 or visit www.leddental.com.

Forward Looking Statements

This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the capabilities and usage of the Company's product offerings and the potential expansion of the Company's technology to other applications or markets. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2012. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information.All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Read more http://www.marketwired.com/mw/release.do?id=1885787&sourceType=3





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 
BioMedReports Abiomed Inc. Announces Clinical Trial Results For RECOVER RIGHT; Oncolytics Reports from US Randomized Phase 2... http://t.co/rQXQtD0YT2
26mreplyretweetfavorite
BioMedReports Healthcare Review: MediciNova, PharmAthene, Rewalk Robotics, Avanir Pharmaceuticals, Northwest Biotherapeutics... http://t.co/ZzWRn8ufV9
5hreplyretweetfavorite
BioMedReports FDA Approves Baxter's RIXUBIS; TG Therapeutics Announces Special Protocol Assessment Agreement With The FDA fo... http://t.co/Gd1UMfnqVZ
navigation
Benzinga.com supporter Seeking Alpha Certified